Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism

Drugs of Today
Jean-Charles Fruchart, P Duriez

Abstract

Epidemiological studies have shown that hypertriglyceridemia and low HDL-cholesterol were both associated with an increased risk of coronary heart disease. Furthermore, hypertriglyceridemia is now recognized as an independent risk factor for coronary artery disease. Secondary prevention trials (e.g., LOCAT, BECAIT, BIP and DAIS) in coronary artery disease with drugs acting primarily on triglycerides (e.g., the PPAR-alpha activators bezafibrate, fenofibrate and gemfibrozil) have shown that reducing triglycerides and increasing HDL-cholesterol, without significantly affecting LDL-cholesterol, slows down coronary artery luminal narrowing. Furthermore, the VA-HIT study recently showed that gemfibrozil decreased coronary artery disease mortality in secondary prevention trials, partly by increasing HDL-cholesterol. The peroxisome proliferator-activated receptors (PPARs) (i.e., PPAR-alpha, -beta(delta) and -gamma) form a subfamily of the nuclear receptor gene family. Whereas all PPARs are, albeit to differing extents, activated by fatty acids and derivatives, PPAR-alpha binds the hypolipidemic fibrates. PPAR-alpha activation mediates changes in lipoprotein metabolism. Moreover, PPAR-alpha activators increase hepatic uptake and esterif...Continue Reading

Citations

Jun 22, 2014·Cardiovascular Research·Alan T RemaleyAlberico L Catapano
Mar 28, 2008·Current Diabetes Reports·John A Farmer
Mar 9, 2011·Proceedings of the National Academy of Sciences of the United States of America·Frédéric GachonUeli Schibler
Sep 13, 2013·Nutrients·Hashim A PeriyalilLisa G Wood
Mar 13, 2014·Journal of the American College of Nutrition·Donato CasamassimaLuigi Ambrosone
Oct 19, 2010·Journal of Obesity·Barry Sears, Camillo Ricordi
Sep 20, 2007·Current Atherosclerosis Reports·John A Farmer
Mar 24, 2016·Gastroenterology Research and Practice·Newaz HossainSmruti R Mohanty
Feb 5, 2008·Atherosclerosis·Mahdi GarelnabiSampath Parthasarathy
Oct 3, 2012·Cell Biochemistry and Function·Gianella CaiozziMarie-Louise Ricketts
Apr 11, 2012·British Journal of Clinical Pharmacology·Michael Oliver
Oct 7, 2006·Biochemical and Biophysical Research Communications·Markus NeumeierChrista Buechler
Jan 1, 2012·Scientifica·Giuseppe Danilo Norata
Jul 8, 2010·Expert Opinion on Drug Metabolism & Toxicology·Divya Samineni, Carl J Fichtenbaum
Sep 24, 2008·Expert Opinion on Investigational Drugs·Theodosios Filippatos, Haralampos J Milionis
Dec 3, 2013·Journal of Pharmacological Sciences·Minako KarahashiNaomi Kudo
Sep 19, 2009·Nutrition & Metabolism·Sailas Benjamin, Friedrich Spener
Aug 24, 2013·PloS One·Maria KonstandiFrank J Gonzalez
May 23, 2012·Progress in Lipid Research·Aneta Otocka-KmiecikMaciej Banach
Jun 24, 2009·Atherosclerosis·Robert S Rosenson
Sep 29, 2007·Journal of Lipid Research·Abdelmadjid K HihiSiegfried Hekimi
Feb 3, 2015·Open Medicine·Anna SkoczyńskaKamila Wojtas
Mar 26, 2009·American Journal of Physiology. Endocrinology and Metabolism·Hong Wang, Robert H Eckel
Apr 27, 2011·Current Opinion in Lipidology·Sandeep A Saha, Rohit R Arora
Jan 27, 2019·Experimental and Therapeutic Medicine·Xiaonan ZhangPing Shi
Oct 29, 2008·Journal of Clinical Pathology·G FernsB Griffin
Oct 3, 2018·Frontiers in Endocrinology·Karel Erion, Barbara E Corkey
Sep 29, 2011·Drugs·Kate McKeage, Gillian M Keating
Sep 17, 2018·Environmental Science and Pollution Research International·Marco CapolupoMaria Laura Martín-Díaz

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.